---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-007983"
form_type: "8-K"
ticker: "PRLD"
cik: "0001678660"
company_name: "Prelude Therapeutics Inc"
filed_at: "2023-03-15T23:59:59+00:00"
generated_at: "2026-06-18T02:09:05.227261+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Prelude Therapeutics reports FY 2022 net loss of $115.4M; cash runway through Q4 2024

## Summary
- Net loss of $115.4M ($2.44 per share) vs $111.7M ($2.43 per share) in FY 2021.
- Cash and equivalents of $201.7M as of Dec 31, 2022; runway extended through Q4 2024.
- R&D expenses $92.9M, G&A $30.7M; both up YoY.
- Clinical trial collaboration with BeiGene to evaluate PRT2527 + zanubrutinib in hematologic malignancies.
- Bryant D. Lim appointed Chief Legal Officer, effective Feb 20, 2023.

## SEC filing metadata
- accession: 0000950170-23-007983
- form_type: 8-K
- ticker: PRLD
- cik: 0001678660
- company_name: Prelude Therapeutics Inc
- filed_at: 2023-03-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1678660/000095017023007983/0000950170-23-007983-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1678660/000095017023007983/prld-20230315.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-007983
- JSON: https://secwatch.observer/filing/0000950170-23-007983.json
- Plain text: https://secwatch.observer/filing/0000950170-23-007983.txt

## Key facts
- Earnings Releases
  Prelude Therapeutics Inc reported financial results for fiscal year ended December 31, 2022.
  - Period: fiscal year ended December 31, 2022
  - Result: reported results
  source text: On March 15, 2023, Prelude Therapeutics Incorporated (the "Company") issued a press release announcing its financial results for the year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1678660/000095017023007983/0000950170-23-007983-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.